05/08/2011
PRESS RELEASE
Vemedia Pharma continues its growth path with the acquisition of Imgroma BV in the Netherlands
05/08/2011
PRESS RELEASE
Vemedia Pharma continues its growth path with the acquisition of Imgroma BV in the Netherlands
17/02/2011
Press release
Vemedia Pharma performs strongly in 2010 and invests in its brands.
Download PDF
21/12/2010
Vemedia Pharma acquires Podosan in Spain and Portugal
As of the 15th of December, Vemedia acquired Podosan, a footcare product line, from Faes Farma for the Spanish and Portugese markets.
01/09/2010
Results 1st. semester 2010 & Acquisition Sleepzz
19/05/2010
Uitnodiging jaarvergadering (& volmacht) 2009 Vemedia Pharma NV
19/05/2010
Jaarrekening 2009 Vemedia Pharma NV (geconsolideerd)
Geconsolideerde financiële staten 2009.
19/05/2010
Jaarverslag commissaris 2009 Vemedia Pharma NV (geconsolideerd)
19/05/2010
Jaarverslag RvB 2009 Vemedia Pharma NV (geconsolideerd)
Jaarverslag over de geconsolideerde jaarrekening van de raad van bestuur aan de algemene vergadering.
02/10/2009
PRESS RELEASE Subordinated Bonds and Subscription Rights
Private placement of Subordinated Bonds and Subscription Rights
16/06/2009
Jaarrekening 2008 Vemedia Pharma NV (geconsolideerd)
Geconsolideerde financiële staten 2008
16/06/2009
Jaarverslag RvB 2008 Vemedia Pharma (geconsolideerd)
Jaarverslag over de geconsolideerde jaarrekening van de raad van bestuur aan de algemene vergadering van 4 juni 2009.
16/06/2009
Verslag commissaris 2008 Vemedia Pharma NV (geconsoldideerd)
17/03/2009
Consolidated Results for Financial Year 2008
Vemedia Pharma experiences international growth due to the acquisition of Valdispert. Revenue increased by 25%, EBITDA more than doubled to € 11.0 million.
15/05/2008
Vemedia acquires Valdispert from Solvay Pharmaceuticals and becomes a European Pharma/OTC player
Vemedia acquires Valdispert/Baldrian valerian root extract tablets, indicated in the treatment of mild to moderate sleeping disorders and states of restlessness and tension. Solvay Pharmaceuticals divests all rights to manufacture and market the products in all territories around the world to Vemedia. To finance this transaction, Vemedia Pharma will increase its capital with 4,5 million Euro, which will be subscribed by existing shareholders ( i.a. Indufin and Leeuward Ventures Sicar ), completed by mezzanine- (KBC Private Equity, Indufin ) and bank loans (Dexia, KBC bank and Rabobank).
25/02/2008
Rhei Pharmaceuticals licenses Attental from MethaPharma (Vemedia Group) for distribution throughout Asia
RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental® throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.
27/07/2007
Acquires MethaPharma (Belgium)
01/05/2007
Vemedia enters into a European deal with Pharmachemie (TEVA-group).
27/04/2007
Results of public offering
Vemedia Pharma NV collects EUR 10,465,662.28 thanks to public offering towards pharmacists, doctors and other investors that were notified in Belgium and the Netherlands.
16/03/2007
Subscribe for new shares
VEMEDIA PHARMA NV will issue, in cooperation with Fortis Bank, an offer to subscribe for an amount of up to EUR 15 million in New Shares with VVPR Strips and an Offer to sell 114.000 Existing Shares as of March 15, 2007.
PRESS RELEASE
Vemedia Pharma continues its growth path with the acquisition of Imgroma BV in the Netherlands
05/08/2011
PRESS RELEASE
Vemedia Pharma continues its growth path with the acquisition of Imgroma BV in the Netherlands
17/02/2011
Press release
Vemedia Pharma performs strongly in 2010 and invests in its brands.
Download PDF
21/12/2010
Vemedia Pharma acquires Podosan in Spain and Portugal
As of the 15th of December, Vemedia acquired Podosan, a footcare product line, from Faes Farma for the Spanish and Portugese markets.
01/09/2010
Results 1st. semester 2010 & Acquisition Sleepzz
19/05/2010
Uitnodiging jaarvergadering (& volmacht) 2009 Vemedia Pharma NV
19/05/2010
Jaarrekening 2009 Vemedia Pharma NV (geconsolideerd)
Geconsolideerde financiële staten 2009.
19/05/2010
Jaarverslag commissaris 2009 Vemedia Pharma NV (geconsolideerd)
19/05/2010
Jaarverslag RvB 2009 Vemedia Pharma NV (geconsolideerd)
Jaarverslag over de geconsolideerde jaarrekening van de raad van bestuur aan de algemene vergadering.
02/10/2009
PRESS RELEASE Subordinated Bonds and Subscription Rights
Private placement of Subordinated Bonds and Subscription Rights
16/06/2009
Jaarrekening 2008 Vemedia Pharma NV (geconsolideerd)
Geconsolideerde financiële staten 2008
16/06/2009
Jaarverslag RvB 2008 Vemedia Pharma (geconsolideerd)
Jaarverslag over de geconsolideerde jaarrekening van de raad van bestuur aan de algemene vergadering van 4 juni 2009.
16/06/2009
Verslag commissaris 2008 Vemedia Pharma NV (geconsoldideerd)
17/03/2009
Consolidated Results for Financial Year 2008
Vemedia Pharma experiences international growth due to the acquisition of Valdispert. Revenue increased by 25%, EBITDA more than doubled to € 11.0 million.
15/05/2008
Vemedia acquires Valdispert from Solvay Pharmaceuticals and becomes a European Pharma/OTC player
Vemedia acquires Valdispert/Baldrian valerian root extract tablets, indicated in the treatment of mild to moderate sleeping disorders and states of restlessness and tension. Solvay Pharmaceuticals divests all rights to manufacture and market the products in all territories around the world to Vemedia. To finance this transaction, Vemedia Pharma will increase its capital with 4,5 million Euro, which will be subscribed by existing shareholders ( i.a. Indufin and Leeuward Ventures Sicar ), completed by mezzanine- (KBC Private Equity, Indufin ) and bank loans (Dexia, KBC bank and Rabobank).
25/02/2008
Rhei Pharmaceuticals licenses Attental from MethaPharma (Vemedia Group) for distribution throughout Asia
RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental® throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.
27/07/2007
Acquires MethaPharma (Belgium)
01/05/2007
Vemedia enters into a European deal with Pharmachemie (TEVA-group).
27/04/2007
Results of public offering
Vemedia Pharma NV collects EUR 10,465,662.28 thanks to public offering towards pharmacists, doctors and other investors that were notified in Belgium and the Netherlands.
16/03/2007
Subscribe for new shares
VEMEDIA PHARMA NV will issue, in cooperation with Fortis Bank, an offer to subscribe for an amount of up to EUR 15 million in New Shares with VVPR Strips and an Offer to sell 114.000 Existing Shares as of March 15, 2007.